HR Execs on the Move

Invitae

www.invitae.com

 
Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world`s medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.invitae.com
  • 1400, 16th Street
    San Francisco, CA USA 94103
  • Phone: 415.374.7782

Executives

Name Title Contact Details
Ana Schrank
 Chief Financial Officer Profile
Robert Dickey
 Interim Chief Financial Officer Profile
Robert Dickey
 Interim Chief Financial Officer Profile
Matt Willmon
 Vice President, Total Rewards Profile
Eric Olivares
 Head of Research And Development Profile

Similar Companies

Main OfficeReaction Design

Main OfficeReaction Design is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Elysium Health

Elysium`s mission is to solve the biggest challenges in health with science, to help people live healthier, longer lives. Working directly with the world`s leading scientists and clinicians, Elysium translates advances in science and technology into effective, scientifically sound health products that work.

Organogenesis

Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BionorImmuno

BionorImmuno is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marina Biotech

Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103